Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Iradimed Earnings Call: Key Takeaways

Iradimed delivered record Q3 revenue driven by the 3870 pump launch, though management lowered the top-end of full-year revenue guidance due to production ramp constraints.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthPump revenue $8.7M (up 4%); Monitor revenue $8M (up 17%); Disposables $5M.
Mgmt ConfidenceHigh confidence in 3870 pump demand; cautious on manufacturing ramp speed.
Demand VisibilityRecord bookings for monitors and pumps; 3870 backlog growing after 300 shipments.
Order BookRecord Q3 bookings; comfortable backlog for Q4 across all product lines.
Margin TrendsGross margin 76%; sequential improvement of 2 points from Q2 efficiencies.
Op. LeverageOperating expenses declined to 43% of revenue from 46% year-over-year.
Pricing PowerNew 3870 pump commands $25,000 ASP, a 23-25% lift over 3860.
Vol vs PriceGrowth driven by both higher ASP and increased channel volume (quad-stacks).
Segment GrowthInternational revenue grew 45%; domestic revenue grew 9% in Q3.
New ClientsSecured orders from 'greenfield' facilities that previously rejected older pump models.
Capex & DebtCash at $63.3M; CapEx $0.2M; quarterly dividend declared at $0.20.
CommentaryFocusing on replacing 6,400 older pump channels with higher-margin quad-stack systems.
New LaunchesSuccessful broad market launch of 3870 MRIV pump; expanded monitor remote capabilities.

Growth

Revenue grew 14% YoY to $24.2M; international revenue surged 45% to $4.5M.

Outlook

Targeting $100M+ annualized run rate in Q4; 2027 revenue growth expected in upper-teens.

Risks

Management lowered full-year revenue ceiling by $2.8M, citing quality-control limits on production ramp speeds.

Source

The company's earnings call, NASDAQ: IRMD, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Iradimed Corp: key numbers

Share price
$84.84Close, Nov 16
Market cap
$1.08B
Shares outstanding
12.79MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Iradimed Corp

All →
8:37 AM ET 8-K
Financial Results

Iradimed Financial Results

IRADIMED reported record Q3 2026 revenue of $24.2 million, a 14% year-over-year increase driven by the launch of its new 3870 MR IV pump. The company also declared a quarterly cash dividend of $0.20 per share and updated its full-year 2026 revenue guidance to a range of $91.6 million to $93.1 million.

Term
Q3 2026

“We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump. As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected.”

Roger Susi, President and Chief Executive Officer of Iradimed

“For the fourth quarter of 2026, we expect revenue of $25.0 million to $26.5 million, attaining a $100.0 million revenue run rate while generating GAAP diluted earnings per share of $0.53 to $0.57 and non-GAAP diluted earnings per share of $0.57 to $0.61.”

Roger Susi, President and Chief Executive Officer of Iradimed

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.